Protein Biomarkers for Early Detection of Pancreatic Ductal Adenocarcinoma: Progress and Challenges

Approximately 75% of patients with pancreatic ductal adenocarcinoma are diagnosed with advanced cancer, which cannot be safely resected. The most commonly used biomarker CA19-9 has inadequate sensitivity and specificity for early detection, which we define as Stage I/II cancers. Therefore, progress...

Descripción completa

Detalles Bibliográficos
Autores principales: Root, Alex, Allen, Peter, Tempst, Paul, Yu, Kenneth
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2018
Materias:
Perspective
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5876642/
https://www.ncbi.nlm.nih.gov/pubmed/29518918
http://dx.doi.org/10.3390/cancers10030067

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5876642/
https://www.ncbi.nlm.nih.gov/pubmed/29518918
http://dx.doi.org/10.3390/cancers10030067

Ejemplares similares